Back to All Combinations

RAS/BRAF Wild-Type (Right)

Intermediate Prognosis
10.00% Prevalence Level 2A RAS Pathway
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
KRAS NRAS BRAF
Treatment Implications

Despite RAS WT, right-sided benefit less from anti-EGFR.

Recommended Treatments
FOLFOX + Bevacizumab
FOLFOXIRI + Bevacizumab
Treatments to Avoid

No specific contraindications noted

Study References

CALGB 80405

Key Statistics
10.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Bevacizumab may be preferred first-line.
Information

Category: RAS Pathway

Evidence Level: Level 2A

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.